Senate Bill S6758B

2025-2026 Legislative Session

Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

download bill text pdf

Current Bill Status - In Assembly Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

Date of Action	Assembly Actions - Lowercase Senate Actions - UPPERCASE
May 29, 2026	referred to health delivered to assembly passed senate
May 14, 2026	advanced to third reading
May 13, 2026	2nd report cal.
May 12, 2026	1st report cal.1095
May 05, 2026	print number 6758b
May 05, 2026	amend and recommit to health
Jan 16, 2026	print number 6758a
Jan 16, 2026	amend and recommit to health
Jan 07, 2026	referred to health
Mar 24, 2025	referred to health

Votes

- May 12, 2026 - Health Committee Vote
  S6758B
  
  Aye
  
  10
  
  Nay
  
  0
  
  Aye with Reservations
  
  4
  
  Absent
  
  0
  
  Excused
  
  1
  
  Abstained
  
  0
  - - Health Committee Vote: May 12, 2026
      
      aye (10)
      
      Ashby
      
      Brouk
      
      Gonzalez
      
      Jackson
      
      May
      
      Myrie
      
      Parker
      
      Rivera
      
      Ryan
      
      Webb
      
      aye wr (4)
      
      Gallivan
      
      Martins
      
      Rhoads
      
      Stec
      
      excused (1)
      
      Sutton

Bill Amendments

Original

B (Active)

2025-S6758 - Details

See Assembly Version of this Bill:: A9010
Current Committee:: Assembly Health
Law Section:: Public Health Law
Laws Affected:: Amd §§3331 & 3309, Pub Health L

2025-S6758 - Summary

Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

2025-S6758 - Sponsor Memo

                                 
BILL NUMBER: S6758

SPONSOR: FERNANDEZ
 
TITLE OF BILL:

An act to amend the public health law, in relation to requiring practi-
tioners to discuss certain risks with a patient who is being prescribed
a controlled substance or an opioid analgesic

 
PURPOSE OR GENERAL IDEA OF BILL:

Amends the public health law to better protect the health and safety of
patients undergoing opioid or related schedule II controlled substance
prescription dosage for treatment as well as inform patients of the
side-effects that may result from such use.

 
SUMMARY OF PROVISIONS:

Section 1 adds subparagraph (b) to subdivision 9 of section 3331 of the
public health law to specify what must be discussed between patient and
physician regarding the risks associated with the drugs being
prescribed.

Section 2 adds subparagraph (vii) to paragraph (a) of subdivision 3 of
section 3309 of the public health law to include the definition of
opioid analgesics.

Section 3 amends subdivision 7 of section 3309 of the public health law,
to clarify language and mandate discussion with the patient on the risks
of overdose.

Section 4 provides the effective date.

 
JUSTIFICATION:

When patients are given opioid and other schedule II controlled
substance prescriptions for pain relief, they are often uninformed of
the risks and side-effects associated with the use of aforesaid medica-
tions, such as physical and psychological dependencies and misuse. More-
over, providers frequently neglect providing information of alternative
prescriptions available to them, or why the prescription is necessary to
their well-being. This legislation will help in preventing patients from
being left in the dark regarding the risk management, side effects,
alternative methods, and imperatives of their prescribed medication.

 
PRIOR LEGISLATIVE HISTORY:

New bill.

 
FISCAL IMPLICATIONS:

None to the state.

 
EFFECTIVE DATE:
This act shall take effect immediately.

2025-S6758 - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   6758
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                              March 24, 2025
                                ___________
 
 Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
   printed to be committed to the Committee on Health
 
 AN  ACT to amend the public health law, in relation to requiring practi-
   tioners  to  discuss  certain  risks  with  a  patient  who  is  being
   prescribed a controlled substance or an opioid analgesic

   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision 9 of section 3331 of the public health law,  as
 added by chapter 732 of the laws of 2022, is amended to read as follows:
   9.  (a)  When  a  patient seeks treatment for any neuromusculoskeletal
 condition that causes pain, where a practitioner  considers  [an  opioid
 treatment]  PRESCRIPTION  OF  A SCHEDULE II CONTROLLED SUBSTANCE FOR THE
 TREATMENT OF PAIN OR ANY OTHER OPIOID DRUG WHICH IS A PRESCRIPTION  DRUG
 FOR  ACUTE  OR  CHRONIC  PAIN  AND  AGAIN  PRIOR  TO  ISSUING  THE THIRD
 PRESCRIPTION OF THE COURSE OF TREATMENT, the practitioner shall  consid-
 er,  discuss  with  the  patient  AS  SET FORTH IN PARAGRAPH (B) OF THIS
 SUBDIVISION, and, as appropriate, refer or prescribe  non-opioid  treat-
 ment  alternatives,  based  on  the practitioner's clinical judgment and
 following generally accepted national professional or  treatment  guide-
 lines, and consistent with patient preference and consent, before start-
 ing a patient on opioid treatment. For the purposes of this subdivision,
 non-opioid  treatment  alternatives  include,  but  are  not limited to:
 acupuncture, chiropractic, massage therapy,  physical  therapy,  occupa-
 tional  therapy,  cognitive  behavioral therapy, non-opioid medications,
 interventional treatments and non-clinical activities such as  exercise.
 The  practitioner  shall inform the patient that some treatments may not
 be covered by the patient's health coverage.
   (b) A PRACTITIONER SHALL DISCUSS WITH THE PATIENT,  OR  THE  PATIENT'S
 PARENT  OR GUARDIAN IF THE PATIENT IS UNDER EIGHTEEN YEARS OF AGE AND IS
 NOT AN EMANCIPATED MINOR, THE RISKS  ASSOCIATED  WITH  THE  DRUGS  BEING
 PRESCRIBED, INCLUDING BUT NOT LIMITED TO:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11164-01-5

 S. 6758                             2
 
   (I)  THE  RISKS OF ADDICTION AND OVERDOSE ASSOCIATED WITH OPIOID DRUGS
 AND THE DANGERS OF TAKING OPIOID DRUGS WITH ALCOHOL, BENZODIAZEPINES AND
 OTHER CENTRAL NERVOUS SYSTEM DEPRESSANTS;
   (II) THE REASONS WHY THE PRESCRIPTION IS NECESSARY;
   (III) ALTERNATIVE TREATMENTS THAT MAY BE AVAILABLE; AND
   (IV)  THE RISKS ASSOCIATED WITH THE USE OF THE DRUGS BEING PRESCRIBED,
 SPECIFICALLY THAT OPIOIDS ARE  HIGHLY  ADDICTIVE,  EVEN  WHEN  TAKEN  AS
 PRESCRIBED,  THAT THERE IS A RISK OF DEVELOPING A PHYSICAL OR PSYCHOLOG-
 ICAL DEPENDENCE ON THE CONTROLLED  SUBSTANCE,  AND  THAT  THE  RISKS  OF
 TAKING  MORE  OPIOIDS  THAN PRESCRIBED, OR MIXING SEDATIVES, BENZODIAZE-
 PINES  OR  ALCOHOL  WITH  OPIOIDS,  CAN  RESULT  IN  FATAL   RESPIRATORY
 DEPRESSION.
   (C)  THE  DEPARTMENT SHALL DEVELOP AND MAKE AVAILABLE TO PRACTITIONERS
 GUIDELINES FOR THE DISCUSSION REQUIRED BY THIS SUBDIVISION.
   (D) The requirements of this subdivision shall not apply for  patients
 being  treated  under  any of the following circumstances:  treatment of
 cancer; hospice or other end-of-life care; post-surgery treatment  imme-
 diately  following a surgical procedure; or in a medical emergency.  For
 purposes of this subdivision, "medical emergency" means an acute  injury
 or illness that poses an immediate risk to a person's life or health.
   §  2.  Paragraph  (a)  of  subdivision 3 of section 3309 of the public
 health law is amended by adding a new  subparagraph  (vii)  to  read  as
 follows:
   (VII) "OPIOID ANALGESICS" MEANS THE MEDICINES BUPRENORPHINE, BUTORPHA-
 NOL,   CODEINE,  HYDROCODONE,  HYDROMORPHONE,  LEVORPHANOL,  MEPERIDINE,
 METHADONE, MORPHINE, NALBUPHINE,  OXYCODONE,  OXYMORPHONE,  PENTAZOCINE,
 PROPOXYPHENE AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
   §  3. Subdivision 7 of section 3309 of the public health law, as added
 by chapter 803 of the laws of 2021, is amended to read as follows:
   7. [With] FOR the first OPIOID ANALGESIC prescription [to a particular
 patient] of [an opioid of each] A CALENDAR year THAT IS GREATER  THAN  A
 ONE WEEK'S SUPPLY, for use in a setting other than a general hospital or
 nursing  home  under  article  twenty-eight  of this chapter or facility
 under article thirty-one of the mental hygiene law, or  when  a  practi-
 tioner is prescribing a controlled substance to a patient under the care
 of  hospice as defined by section four thousand two of this chapter, the
 prescriber shall COUNSEL THE PATIENT  ON  THE  RISKS  OF  OVERDOSE,  AND
 prescribe  an  opioid  antagonist when any of the following risk factors
 are present: (a) a history of substance use disorder; (b) high  dose  or
 cumulative prescriptions that result in ninety morphine milligram equiv-
 alents  or higher per day; (c) concurrent use of opioids and benzodiaze-
 pine or nonbenzodiazepine sedative hypnotics.
   § 4. This act shall take effect immediately.

co-Sponsors

2025-S6758A - Details

See Assembly Version of this Bill:: A9010
Current Committee:: Assembly Health
Law Section:: Public Health Law
Laws Affected:: Amd §§3331 & 3309, Pub Health L

2025-S6758A - Summary

2025-S6758A - Sponsor Memo

                                 
BILL NUMBER: S6758A

SPONSOR: FERNANDEZ
 
TITLE OF BILL:

An act to amend the public health law, in relation to requiring practi-
tioners to discuss certain risks with a patient who is being prescribed
a controlled substance or an opioid analgesic

 
PURPOSE OR GENERAL IDEA OF BILL:

Amends the public health law to better protect the health and safety of
patients undergoing opioid or related schedule II controlled substance
prescription dosage for treatment as well as inform patients of the
side-effects that may result from such use.

 
SUMMARY OF PROVISIONS:

Section 1 adds subparagraph (b) to subdivision 9 of section 3331 of the
public health law to specify what must be discussed between patient and
physician regarding the risks associated with the drugs being
prescribed.

Section 2 adds subparagraph (vii) to paragraph (a) of subdivision 3 of
section 3309 of the public health law to include the definition of
opioid analgesics.

Section 3 amends subdivision 7 of section 3309 of the public health law,
to clarify language and mandate discussion with the patient on the risks
of overdose.

Section 4 provides the effective date.

 
JUSTIFICATION:

When patients are given opioid and other schedule II controlled
substance prescriptions for pain relief, they are often uninformed of
the risks and side-effects associated with the use of aforesaid medica-
tions, such as physical and psychological dependencies and misuse. More-
over, providers frequently neglect providing information of alternative
prescriptions available to them, or why the prescription is necessary to
their well-being. This legislation will help in preventing patients from
being left in the dark regarding the risk management, side effects,
alternative methods, and imperatives of their prescribed medication.

 
PRIOR LEGISLATIVE HISTORY:

New bill.

 
FISCAL IMPLICATIONS:

None to the state.

 
EFFECTIVE DATE:
This act shall take effect immediately.

2025-S6758A - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  6758--A
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                              March 24, 2025
                                ___________
 
 Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
   printed  to  be committed to the Committee on Health -- recommitted to
   the Committee on Health in accordance with Senate Rule 6,  sec.  8  --
   committee  discharged,  bill amended, ordered reprinted as amended and
   recommitted to said committee

 AN ACT to amend the public health law, in relation to requiring  practi-
   tioners  to  discuss  certain  risks  with  a  patient  who  is  being
   prescribed a controlled substance or an opioid analgesic
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1. Subdivision 9 of section 3331 of the public health law, as
 added by chapter 732 of the laws of 2022, is amended to read as follows:
   9. (a) When a patient seeks treatment for  any  [neuromusculoskeletal]
 condition  that  causes  pain, where a practitioner considers [an opioid
 treatment] PRESCRIPTION OF A SCHEDULE II CONTROLLED  SUBSTANCE  FOR  THE
 TREATMENT  OF PAIN OR ANY OTHER OPIOID DRUG WHICH IS A PRESCRIPTION DRUG
 FOR ACUTE  OR  CHRONIC  PAIN  AND  AGAIN  PRIOR  TO  ISSUING  THE  THIRD
 PRESCRIPTION  OF THE COURSE OF TREATMENT, the practitioner shall consid-
 er, discuss with the patient AS SET  FORTH  IN  PARAGRAPH  (B)  OF  THIS
 SUBDIVISION,  and,  as appropriate, refer or prescribe non-opioid treat-
 ment alternatives, based on the  practitioner's  clinical  judgment  and
 following  generally  accepted national professional or treatment guide-
 lines, and consistent with patient preference and consent, before start-
 ing a patient on opioid treatment. For the purposes of this subdivision,
 non-opioid treatment alternatives  include,  but  are  not  limited  to:
 acupuncture,  chiropractic,  massage  therapy, physical therapy, occupa-
 tional therapy, cognitive behavioral  therapy,  non-opioid  medications,
 interventional  treatments and non-clinical activities such as exercise.
 The practitioner shall inform the patient that some treatments  may  not
 be covered by the patient's health coverage.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11164-02-5
 S. 6758--A                          2

 
   (b)  A  PRACTITIONER  SHALL DISCUSS WITH THE PATIENT, OR THE PATIENT'S
 PARENT OR GUARDIAN IF THE PATIENT IS UNDER EIGHTEEN YEARS OF AGE AND  IS
 NOT  AN  EMANCIPATED  MINOR,  THE  RISKS ASSOCIATED WITH THE DRUGS BEING
 PRESCRIBED, INCLUDING BUT NOT LIMITED TO:
   (I)  THE  RISKS OF ADDICTION AND OVERDOSE ASSOCIATED WITH OPIOID DRUGS
 AND THE DANGERS OF TAKING OPIOID DRUGS WITH ALCOHOL, BENZODIAZEPINES AND
 OTHER CENTRAL NERVOUS SYSTEM DEPRESSANTS;
   (II) THE REASONS WHY THE PRESCRIPTION IS NECESSARY;
   (III) ALTERNATIVE TREATMENTS THAT MAY BE AVAILABLE; AND
   (IV) THE RISKS ASSOCIATED WITH THE USE OF THE DRUGS BEING  PRESCRIBED,
 SPECIFICALLY  THAT  OPIOIDS  ARE  HIGHLY  ADDICTIVE,  EVEN WHEN TAKEN AS
 PRESCRIBED, THAT THERE IS A RISK OF DEVELOPING A PHYSICAL OR  PSYCHOLOG-
 ICAL  DEPENDENCE  ON  THE  CONTROLLED  SUBSTANCE,  AND THAT THE RISKS OF
 TAKING MORE OPIOIDS THAN PRESCRIBED, OR  MIXING  SEDATIVES,  BENZODIAZE-
 PINES   OR  ALCOHOL  WITH  OPIOIDS,  CAN  RESULT  IN  FATAL  RESPIRATORY
 DEPRESSION.
   (C) THE DEPARTMENT SHALL DEVELOP AND MAKE AVAILABLE  TO  PRACTITIONERS
 GUIDELINES FOR THE DISCUSSION REQUIRED BY THIS SUBDIVISION.
   (D)  The requirements of this subdivision shall not apply for patients
 being treated under any of the following circumstances:    treatment  of
 cancer;  hospice or other end-of-life care; post-surgery treatment imme-
 diately following a surgical procedure; or in a medical emergency.   For
 purposes  of this subdivision, "medical emergency" means an acute injury
 or illness that poses an immediate risk to a person's life or health.
   § 2. Paragraph (a) of subdivision 3 of  section  3309  of  the  public
 health  law  is  amended  by  adding a new subparagraph (vii) to read as
 follows:
   (VII) "OPIOID ANALGESICS" MEANS THE MEDICINES BUPRENORPHINE, BUTORPHA-
 NOL,  CODEINE,  HYDROCODONE,  HYDROMORPHONE,  LEVORPHANOL,   MEPERIDINE,
 METHADONE,  MORPHINE,  NALBUPHINE,  OXYCODONE, OXYMORPHONE, PENTAZOCINE,
 PROPOXYPHENE AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
   § 3. Subdivision 7 of section 3309 of the public health law, as  added
 by chapter 803 of the laws of 2021, is amended to read as follows:
   7. [With] FOR the first OPIOID ANALGESIC prescription [to a particular
 patient]  of  [an opioid of each] A CALENDAR year THAT IS GREATER THAN A
 ONE WEEK'S SUPPLY, for use in a setting other than a general hospital or
 nursing home under article twenty-eight  of  this  chapter  or  facility
 under  article  thirty-one  of the mental hygiene law, or when a practi-
 tioner is prescribing a controlled substance to a patient under the care
 of hospice as defined by section four thousand two of this chapter,  the
 prescriber  shall  COUNSEL  THE  PATIENT  ON  THE RISKS OF OVERDOSE, AND
 prescribe an opioid antagonist when any of the  following  risk  factors
 are  present:  (a) a history of substance use disorder; (b) high dose or
 cumulative prescriptions that result in ninety morphine milligram equiv-
 alents or higher per day; (c) concurrent use of opioids and  benzodiaze-
 pine or nonbenzodiazepine sedative hypnotics.
   § 4. This act shall take effect immediately.

co-Sponsors

View additional co-sponsors

2025-S6758B (ACTIVE) - Details

See Assembly Version of this Bill:: A9010
Current Committee:: Assembly Health
Law Section:: Public Health Law
Laws Affected:: Amd §§3331 & 3309, Pub Health L

2025-S6758B (ACTIVE) - Summary

2025-S6758B (ACTIVE) - Sponsor Memo

                                 
BILL NUMBER: S6758B

SPONSOR: FERNANDEZ
 
TITLE OF BILL:

An act to amend the public health law, in relation to requiring practi-
tioners to discuss certain risks with a patient who is being prescribed
a controlled substance or an opioid analgesic

 
PURPOSE OR GENERAL IDEA OF BILL:

Amends the public health law to better protect the health and safety of
patients undergoing opioid prescription dosage for treatment as well as
inform patients of the side-effects that may result from such use.

 
SUMMARY OF PROVISIONS:

Section 1 adds subparagraph (b) to subdivision 9 of section 3331 of the
public health law to specify what must be discussed between patient and
physician regarding the risks associated with the drugs being
prescribed.

Section 2 adds subparagraph (vii) to paragraph (a) of subdivision 3 of
section 3309 of the public health law to include the definition of
opioid analgesics.

Section 3 amends subdivision 7 of section 3309 of the public health law,
to clarify language and mandate discussion with the patient on the risks
of overdose.

Section 4 provides the effective date.

 
JUSTIFICATION:

When patients are given opioid prescriptions for pain relief, they are
often uninformed of the risks and side-effects associated with the use
of aforesaid medications, such as physical and psychological dependen-
cies and misuse. Moreover, providers frequently neglect providing infor-
mation of alternative prescriptions available to them, or why the
prescription is necessary to their well-being. This legislation will
help in preventing patients from being left in the dark regarding the
risk management, side effects, alternative methods, and imperatives of
their prescribed medication.

 
PRIOR LEGISLATIVE HISTORY:

New bill.

 
FISCAL IMPLICATIONS:

None to the state.

 
EFFECTIVE DATE:
This act shall take effect immediately.

2025-S6758B (ACTIVE) - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  6758--B
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                              March 24, 2025
                                ___________
 
 Introduced  by  Sens.  FERNANDEZ, BORRELLO, HARCKHAM, RIVERA, C. RYAN --
   read twice and ordered printed, and when printed to  be  committed  to
   the  Committee  on Health -- recommitted to the Committee on Health in
   accordance with Senate Rule 6, sec. 8 --  committee  discharged,  bill
   amended,  ordered reprinted as amended and recommitted to said commit-
   tee --  committee  discharged,  bill  amended,  ordered  reprinted  as
   amended and recommitted to said committee
 
 AN  ACT to amend the public health law, in relation to requiring practi-
   tioners  to  discuss  certain  risks  with  a  patient  who  is  being
   prescribed a controlled substance or an opioid analgesic
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision 9 of section 3331 of the public health law,  as
 added by chapter 732 of the laws of 2022, is amended to read as follows:
   9.  (a)  When a patient seeks treatment for any [neuromusculoskeletal]
 condition that causes pain, where a practitioner  considers  [an  opioid
 treatment]   PRESCRIPTION  OF  ANY  OPIOID  DRUG  WHICH  IS  AN  INITIAL
 PRESCRIPTION FOR ACUTE OR CHRONIC PAIN AND AGAIN PRIOR  TO  ISSUING  THE
 THIRD  PRESCRIPTION  OF  THE COURSE OF TREATMENT, the practitioner shall
 consider, discuss with the patient AS SET FORTH IN PARAGRAPH (B) OF THIS
 SUBDIVISION, and, as appropriate, refer or prescribe  non-opioid  treat-
 ment  alternatives,  based  on  the practitioner's clinical judgment and
 following generally accepted national professional or  treatment  guide-
 lines, and consistent with patient preference and consent, before start-
 ing a patient on opioid treatment. For the purposes of this subdivision,
 non-opioid  treatment  alternatives  include,  but  are  not limited to:
 acupuncture, chiropractic, massage therapy,  physical  therapy,  occupa-
 tional  therapy,  cognitive  behavioral therapy, non-opioid medications,
 interventional treatments and non-clinical activities such as  exercise.
 The  practitioner  shall inform the patient that some treatments may not
 be covered by the patient's health coverage.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11164-04-6

 S. 6758--B                          2
 
   (b) A PRACTITIONER SHALL DISCUSS WITH THE PATIENT,  OR  THE  PATIENT'S
 PARENT  OR GUARDIAN IF THE PATIENT IS UNDER EIGHTEEN YEARS OF AGE AND IS
 NOT AN EMANCIPATED MINOR, THE RISKS  ASSOCIATED  WITH  THE  DRUGS  BEING
 PRESCRIBED, INCLUDING BUT NOT LIMITED TO:
   (I)  THE  RISKS OF ADDICTION AND OVERDOSE ASSOCIATED WITH OPIOID DRUGS
 AND THE DANGERS OF TAKING OPIOID DRUGS WITH ALCOHOL, BENZODIAZEPINES AND
 OTHER CENTRAL NERVOUS SYSTEM DEPRESSANTS;
   (II) THE REASONS WHY THE PRESCRIPTION IS NECESSARY;
   (III) ALTERNATIVE TREATMENTS THAT MAY BE AVAILABLE; AND
   (IV) THE RISKS ASSOCIATED WITH THE USE OF THE DRUGS BEING  PRESCRIBED,
 SPECIFICALLY  THAT  OPIOIDS  ARE  HIGHLY  ADDICTIVE,  EVEN WHEN TAKEN AS
 PRESCRIBED, THAT THERE IS A RISK OF DEVELOPING A PHYSICAL OR  PSYCHOLOG-
 ICAL  DEPENDENCE  ON  THE  CONTROLLED  SUBSTANCE,  AND THAT THE RISKS OF
 TAKING MORE OPIOIDS THAN PRESCRIBED, OR  MIXING  SEDATIVES,  BENZODIAZE-
 PINES   OR  ALCOHOL  WITH  OPIOIDS,  CAN  RESULT  IN  FATAL  RESPIRATORY
 DEPRESSION.
   (C) THE DEPARTMENT SHALL DEVELOP AND MAKE AVAILABLE  TO  PRACTITIONERS
 GUIDELINES FOR THE DISCUSSION REQUIRED BY THIS SUBDIVISION.
   (D)  The requirements of this subdivision shall not apply for patients
 being treated under any of the following circumstances:    treatment  of
 cancer;  hospice or other end-of-life care; post-surgery treatment imme-
 diately following a surgical procedure; or in a medical emergency.   For
 purposes  of this subdivision, "medical emergency" means an acute injury
 or illness that poses an immediate risk to a person's life or health.
   § 2. Paragraph (a) of subdivision 3 of  section  3309  of  the  public
 health  law  is  amended  by  adding a new subparagraph (vii) to read as
 follows:
   (VII) "OPIOID ANALGESICS" MEANS THE MEDICINES BUPRENORPHINE, BUTORPHA-
 NOL,  CODEINE,  HYDROCODONE,  HYDROMORPHONE,  LEVORPHANOL,   MEPERIDINE,
 METHADONE,  MORPHINE,  NALBUPHINE,  OXYCODONE, OXYMORPHONE, PENTAZOCINE,
 PROPOXYPHENE AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
   § 3. Subdivision 7 of section 3309 of the public health law, as  added
 by chapter 803 of the laws of 2021, is amended to read as follows:
   7. [With] FOR the first OPIOID ANALGESIC prescription [to a particular
 patient]  of  [an opioid of each] A CALENDAR year THAT IS GREATER THAN A
 ONE WEEK'S SUPPLY, for use in a setting other than a general hospital or
 nursing home under article twenty-eight  of  this  chapter  or  facility
 under  article  thirty-one  of the mental hygiene law, or when a practi-
 tioner is prescribing a controlled substance to a patient under the care
 of hospice as defined by section four thousand two of this chapter,  the
 prescriber  shall  COUNSEL  THE  PATIENT  ON  THE RISKS OF OVERDOSE, AND
 prescribe an opioid antagonist when any of the  following  risk  factors
 are  present:  (a) a history of substance use disorder; (b) high dose or
 cumulative prescriptions that result in ninety morphine milligram equiv-
 alents or higher per day; (c) concurrent use of opioids and  benzodiaze-
 pine or nonbenzodiazepine sedative hypnotics.
   § 4. This act shall take effect immediately.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Find your Senator and share your views on important issues.

Do you support this bill?

Senate Bill S6758B

Sponsored By

Current Bill Status - In Assembly Committee

Actions

Votes

May 12, 2026 - Health Committee Vote

Health Committee Vote: May 12, 2026

Bill Amendments

2025-S6758 - Details

2025-S6758 - Summary

2025-S6758 - Sponsor Memo

2025-S6758 - Bill Text download pdf

co-Sponsors

2025-S6758A - Details

2025-S6758A - Summary

2025-S6758A - Sponsor Memo

2025-S6758A - Bill Text download pdf

co-Sponsors

2025-S6758B (ACTIVE) - Details

2025-S6758B (ACTIVE) - Summary

2025-S6758B (ACTIVE) - Sponsor Memo

2025-S6758B (ACTIVE) - Bill Text download pdf

Comments

Do you support this bill?

Get Status Alerts for 2025-S6758B

Senate Bill S6758B

Share this bill

Sponsored By

Current Bill Status - In Assembly Committee

Actions

Votes

Bill Amendments

2025-S6758 - Details

2025-S6758 - Summary

2025-S6758 - Sponsor Memo

2025-S6758 - Bill Text download pdf

co-Sponsors

2025-S6758A - Details

2025-S6758A - Summary

2025-S6758A - Sponsor Memo

2025-S6758A - Bill Text download pdf

co-Sponsors

2025-S6758B (ACTIVE) - Details

2025-S6758B (ACTIVE) - Summary

2025-S6758B (ACTIVE) - Sponsor Memo

2025-S6758B (ACTIVE) - Bill Text download pdf

Comments